226 GSK Annual Report 2017 Notes to the financial statements continued 44.
Principal Group companies The following represent the principal subsidiaries and their countries of incorporation of the Group at 31 December 2017.
The equity share capital of these entities is wholly owned by the Group except where its percentage interest is shown otherwise.
All companies are incorporated in their principal country of operation except where stated.
England US Glaxo Group Limited Block Drug Company, Inc. 63.5% Glaxo Operations UK Limited Corixa Corporation GlaxoSmithKline Capital plc GlaxoSmithKline Capital Inc. GlaxoSmithKline Consumer Healthcare Holdings Limited 63.5% GlaxoSmithKline Consumer Healthcare, L. P. 55.9% GlaxoSmithKline Consumer Healthcare UK Trading Limited 63.5% GlaxoSmithKline Holdings Americas Inc. GlaxoSmithKline Export Limited GlaxoSmithKline LLC GlaxoSmithKline Finance plc Human Genome Sciences, Inc. GlaxoSmithKline Holdings Limited GSK Consumer Health, Inc. formerly Novartis Consumer Health, Inc. 63.5% GlaxoSmithKline Research & Development Limited S. R. One, Limited GlaxoSmithKline Services Unlimited Stiefel Laboratories, Inc. GlaxoSmithKline UK Limited ViiV Healthcare Company 78.3% Setfirst Limited SmithKline Beecham Limited ViiV Healthcare Limited 78.3% ViiV Healthcare UK Limited 78.3% Europe Others GlaxoSmithKline Biologicals SA Belgium GlaxoSmithKline Argentina S. A. Argentina GlaxoSmithKline Pharmaceuticals SA Belgium GlaxoSmithKline Australia Pty Ltd Australia GlaxoSmithKline Biologicals S. A. S. France GlaxoSmithKline Consumer Healthcare Australia Pty Ltd Australia 63.5% GlaxoSmithKline Sante Grand Public SAS France 63.5% GlaxoSmithKline Brasil Limitada Brazil Laboratoire GlaxoSmithKline France GlaxoSmithKline Consumer Healthcare Inc. Canada 63.5% ViiV Healthcare SAS France 78.3% GlaxoSmithKline Inc. Canada GlaxoSmithKline Consumer Healthcare GmbH & Co. KG ID Biomedical Corporation of Quebec Canada Germany 63.5% GlaxoSmithKline Limited China Hong Kong GlaxoSmithKline GmbH & Co. KG Germany Sino-American Tianjin Smith Kline & French Laboratories Ltd China 34.9% GSK Vaccines GmbH Germany GlaxoSmithKline Consumer Healthcare Limited India 72.5% GlaxoSmithKline Consumer Healthcare S. p. A. Italy 63.5% GlaxoSmithKline Pharmaceuticals Limited India 75% GlaxoSmithKline S. p. A. Italy GlaxoSmithKline Consumer Healthcare Japan K. K. Japan 63.5% GSK Vaccines S. r. l. Italy GlaxoSmithKline K. K. Japan GlaxoSmithKline B. V. Netherlands ViiV Healthcare Kabushiki Kaisha Japan 78.3% GlaxoSmithKline Consumer Healthcare Sp.
z. o. o. Poland 63.5% GlaxoSmithKline Pakistan Limited Pakistan 82.6% GlaxoSmithKline Pharmaceuticals S. A. Poland Glaxo Wellcome Manufacturing Pte Ltd. Singapore GSK Services Sp z o. o. Poland GlaxoSmithKline Korea Limited Republic of Korea GlaxoSmithKline Trading Services Limited Republic of Ireland i GlaxoSmithKline llaclari Sanayi five Ticaret A. S. Turkey GlaxoSmithKline Healthcare AO Russia 63.5% GlaxoSmithKline S. A. Spain Laboratorios ViiV Healthcare, S. L. Spain 78.3% Novartis Consumer Health S. A. Switzerland 63.5% i E xempt from the provisions of section 347 and 348 of the Companies Act 2014 Ireland, in accordance with the exemptions noted in Section 357 of that Act.
Further subsidiaries, as disclosed on pages 276 to 286, are exempt from these provisions as they are also consolidated in the group financial statements.
Directly held wholly owned subsidiary of GlaxoSmithKline plc.
The subsidiaries and associates listed above principally affect the figures in the Groups financial statements.
Each of GlaxoSmithKline Capital Inc. GlaxoSmithKline Capital plc and GlaxoSmithKline LLC, is a wholly-owned finance subsidiary of the company, and the company has fully and unconditionally guaranteed the securities issued by each of GlaxoSmithKline Capital Inc. GlaxoSmithKline Capital plc and GlaxoSmithKline LLC.
See pages 276 to 286 for a complete list of subsidiary undertakings, associates and joint ventures, which form part of these financial statements.
